Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma.
PEGylated liposome
glioblastoma
nanoparticles
nanotechnology
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
13 Oct 2022
13 Oct 2022
Historique:
received:
10
09
2022
revised:
09
10
2022
accepted:
11
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Glioblastoma is an incurable cancer with a 5-year survival chance of less than 5%. Chemotherapy is a therapeutic approach to treating the disease; however, due to the presence of the blood-brain barrier (BBB), the probability of success is low. To overcome this issue, nanoparticles are promising carriers for crossing the BBB and delivering drugs to the tumor. In this study, the anticancer efficacy of doxorubicin (DOX) and carboplatin (CB) loaded into polyethylene glycol (PEG)ylated liposome nanoparticles (PEG-Lip) and in treating brain cancer was evaluated in vitro and in vivo. The results demonstrated that PEG-Lip-DOX/CB with a size of 212 ± 10 nm was synthesized that could release the loaded drugs in a controlled manner, from which 56.3% of the loaded drugs were released after 52 h. In addition, PEG-Lip-DOX/CB could significantly increase the cytotoxicity effects of the drugs against rat glioma C6 cells (IC
Identifiants
pubmed: 36297618
pii: pharmaceutics14102183
doi: 10.3390/pharmaceutics14102183
pmc: PMC9609487
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Drug Discov Today. 2021 Aug;26(8):1936-1943
pubmed: 33839290
Int J Pharm. 2012 Jul 15;431(1-2):120-9
pubmed: 22569226
J Clin Oncol. 2010 Jul 10;28(20):3323-9
pubmed: 20498395
Mater Sci Eng C Mater Biol Appl. 2019 Apr;97:833-841
pubmed: 30678974
Pharmaceutics. 2022 May 28;14(6):
pubmed: 35745726
Int J Pharm. 2020 Oct 15;588:119792
pubmed: 32827675
J Colloid Interface Sci. 2021 May;589:453-461
pubmed: 33485252
Pharmaceutics. 2022 Jul 29;14(8):
pubmed: 36015204
Biomaterials. 2014 Sep;35(27):7978-91
pubmed: 24939077
Int J Pharm. 2020 May 15;581:119283
pubmed: 32240807
Bioconjug Chem. 2021 Apr 21;32(4):810-820
pubmed: 33843208
J Pharm Sci. 2022 Nov;111(11):3029-3037
pubmed: 35675875
Tumour Biol. 2014 May;35(5):4799-806
pubmed: 24443270
Int J Mol Sci. 2020 Jan 15;21(2):
pubmed: 31952316
Int J Nanomedicine. 2020 Sep 23;15:7035-7049
pubmed: 33061366
NanoImpact. 2022 Jan;25:100384
pubmed: 35559890
Fundam Clin Pharmacol. 2021 Feb;35(1):86-96
pubmed: 32749731
Biomaterials. 2008 Sep;29(26):3583-90
pubmed: 18533252
Pharmaceutics. 2021 Oct 02;13(10):
pubmed: 34683898
Pharmaceutics. 2019 Nov 14;11(11):
pubmed: 31739556
Adv Drug Deliv Rev. 2021 Apr;171:108-138
pubmed: 33486006
Biomaterials. 2022 Jan;280:121077
pubmed: 34890974
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
Biomaterials. 2020 Oct;255:120210
pubmed: 32592871
Int J Pharm. 2014 Apr 10;464(1-2):185-95
pubmed: 24463004
J Photochem Photobiol B. 2020 Jan;203:111773
pubmed: 31931385
Acta Histochem. 2020 Oct;122(7):151625
pubmed: 33066845
Heliyon. 2022 Apr 06;8(4):e09247
pubmed: 35434391
Int J Biol Macromol. 2019 Aug 1;134:815-829
pubmed: 31077697
EXCLI J. 2022 Jan 11;21:236-249
pubmed: 35221842
Pharm Res. 2018 Sep 12;35(11):206
pubmed: 30209680
Bioconjug Chem. 2020 Jul 15;31(7):1820-1834
pubmed: 32543833
RSC Adv. 2018 Sep 6;8(55):31372-31381
pubmed: 35548209
Acta Biochim Pol. 2021 Aug 6;68(4):583-591
pubmed: 34355554
Saudi Pharm J. 2021 May;29(5):434-445
pubmed: 34135669
Mol Pharm. 2019 Jun 3;16(6):2278-2295
pubmed: 31050435
Int J Pharm. 2021 Sep 5;606:120923
pubmed: 34303822
Mater Sci Eng C Mater Biol Appl. 2021 Jan;118:111412
pubmed: 33255014
Life Sci. 2021 Jan 1;264:118605
pubmed: 33096119
J Drug Target. 2016 Sep;24(8):730-43
pubmed: 26878084
Pharmaceutics. 2022 Apr 18;14(4):
pubmed: 35456716
Tumour Biol. 2014 Sep;35(9):8665-72
pubmed: 24867099